Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months

Background: Zidovudine, one of the combination antiretroviral used to treat HIV/AIDS, is the most common cause of anemia in HIV patients. Anemia related to zidovudine in HIV can worsen HIV infection. This study determined the hemoglobin level and effect of zidovudine therapy on HIV naïve patients in...

Full description

Saved in:
Bibliographic Details
Main Authors: PRASETYANING ESTU PRATIWI, NIM011418026311, Usman Hadi, -, Muhammad Vitanata Arfijanto, -
Format: Article PeerReviewed
Language:English
English
English
Published: EManuscript Technologies 2020
Subjects:
Online Access:https://repository.unair.ac.id/126549/1/05%20artikel.pdf
https://repository.unair.ac.id/126549/2/05%20Karil.pdf
https://repository.unair.ac.id/126549/3/05%20Turnitin.pdf
https://repository.unair.ac.id/126549/
https://www.sysrevpharm.org/abstract/hemoglobin-levels-in-patients-with-human-immunodeficiency-virus-nave-therapy-containing-zidovudine-in-the-first-three-mo-65525.html
http://dx.doi.org/10.5530/srp.2019.2.04
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universitas Airlangga
Language: English
English
English
id id-langga.126549
record_format dspace
spelling id-langga.1265492023-05-11T10:35:16Z https://repository.unair.ac.id/126549/ Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months PRASETYANING ESTU PRATIWI, NIM011418026311 Usman Hadi, - Muhammad Vitanata Arfijanto, - RC31-1245 Internal medicine Background: Zidovudine, one of the combination antiretroviral used to treat HIV/AIDS, is the most common cause of anemia in HIV patients. Anemia related to zidovudine in HIV can worsen HIV infection. This study determined the hemoglobin level and effect of zidovudine therapy on HIV naïve patients in the first three months initiation therapy. Methods: Observational analytic study with longitudinal prospective approach was carried out all new HIV patients who received zidovudine therapy. Hemoglobin examination was done at the beginning of the examination and every month for the first three months of zidovudine therapy. Results: Thirteen (38.23%) subjects developed a decrease in hemoglobin levels. The highest incidence of decreased hemoglobin levels in month 2 was in 11 (84.6%) subjects. The mean hemoglobin levels before the initiation of zidovudine ARV and after 3rd month therapy were 12.75±1.57 and 11.94±2.23 g/dl, respectively. The mean decrease in hemoglobin levels of zidovudine therapy was 2.24±1.99 g/dl. There was an effect of three months of zidovudine therapy on decreasing hemoglobin levels in HIV naïve patients with a statistical significance (p = 0.006). Conclusion: There was an effect of zidovudine therapy on decreasing hemoglobin levels in the first three months of ARV therapy HIV naïve patients. EManuscript Technologies 2020 Article PeerReviewed text en https://repository.unair.ac.id/126549/1/05%20artikel.pdf text en https://repository.unair.ac.id/126549/2/05%20Karil.pdf text en https://repository.unair.ac.id/126549/3/05%20Turnitin.pdf PRASETYANING ESTU PRATIWI, NIM011418026311 and Usman Hadi, - and Muhammad Vitanata Arfijanto, - (2020) Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months. Systematic Reviews in Pharmacy, 11 (4). pp. 365-370. ISSN 0976-2779 P-ISSN 0975-8453 https://www.sysrevpharm.org/abstract/hemoglobin-levels-in-patients-with-human-immunodeficiency-virus-nave-therapy-containing-zidovudine-in-the-first-three-mo-65525.html http://dx.doi.org/10.5530/srp.2019.2.04
institution Universitas Airlangga
building Universitas Airlangga Library
continent Asia
country Indonesia
Indonesia
content_provider Universitas Airlangga Library
collection UNAIR Repository
language English
English
English
topic RC31-1245 Internal medicine
spellingShingle RC31-1245 Internal medicine
PRASETYANING ESTU PRATIWI, NIM011418026311
Usman Hadi, -
Muhammad Vitanata Arfijanto, -
Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
description Background: Zidovudine, one of the combination antiretroviral used to treat HIV/AIDS, is the most common cause of anemia in HIV patients. Anemia related to zidovudine in HIV can worsen HIV infection. This study determined the hemoglobin level and effect of zidovudine therapy on HIV naïve patients in the first three months initiation therapy. Methods: Observational analytic study with longitudinal prospective approach was carried out all new HIV patients who received zidovudine therapy. Hemoglobin examination was done at the beginning of the examination and every month for the first three months of zidovudine therapy. Results: Thirteen (38.23%) subjects developed a decrease in hemoglobin levels. The highest incidence of decreased hemoglobin levels in month 2 was in 11 (84.6%) subjects. The mean hemoglobin levels before the initiation of zidovudine ARV and after 3rd month therapy were 12.75±1.57 and 11.94±2.23 g/dl, respectively. The mean decrease in hemoglobin levels of zidovudine therapy was 2.24±1.99 g/dl. There was an effect of three months of zidovudine therapy on decreasing hemoglobin levels in HIV naïve patients with a statistical significance (p = 0.006). Conclusion: There was an effect of zidovudine therapy on decreasing hemoglobin levels in the first three months of ARV therapy HIV naïve patients.
format Article
PeerReviewed
author PRASETYANING ESTU PRATIWI, NIM011418026311
Usman Hadi, -
Muhammad Vitanata Arfijanto, -
author_facet PRASETYANING ESTU PRATIWI, NIM011418026311
Usman Hadi, -
Muhammad Vitanata Arfijanto, -
author_sort PRASETYANING ESTU PRATIWI, NIM011418026311
title Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
title_short Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
title_full Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
title_fullStr Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
title_full_unstemmed Hemoglobin Levels in Patients with Human Immunodeficiency Virus Na ve Therapy Containing Zidovudine in the First Three Months
title_sort hemoglobin levels in patients with human immunodeficiency virus na ve therapy containing zidovudine in the first three months
publisher EManuscript Technologies
publishDate 2020
url https://repository.unair.ac.id/126549/1/05%20artikel.pdf
https://repository.unair.ac.id/126549/2/05%20Karil.pdf
https://repository.unair.ac.id/126549/3/05%20Turnitin.pdf
https://repository.unair.ac.id/126549/
https://www.sysrevpharm.org/abstract/hemoglobin-levels-in-patients-with-human-immunodeficiency-virus-nave-therapy-containing-zidovudine-in-the-first-three-mo-65525.html
http://dx.doi.org/10.5530/srp.2019.2.04
_version_ 1767194218680287232